

Publications related to Lunginnov products

Publications in 2012

Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, Prévot V, Lassalle P, Trouillas J, Delehedde M and Mauraage CA (2012) *Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma.* Brain Pathol. In Press ([Pubmed](#))

Depontieu F, Caires ND, Gourcerol D, Giordano J, Grigoriu B, Delehedde M and Lassalle P (2012) *Development of monoclonal antibodies and ELISA specific for the mouse vascular endocan.* J Immunol Methods. In Press ([Pubmed](#))

Publications in 2011

Akkök CA, Hervig T, Stamnesfet S, Nesthus I, Melve GK, Lassalle P and Bruserud O (2012) *Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma.* Cytotherapy. 13(10):1259-68 ([Pubmed](#))

Carrillo LM, Arciniegas E, Rojas H and Ramirez R (2011) *Immunolocalization of endocan during the endothelial-mesenchymal transition process.* Eur. J. Histochem 55:73-77([ejh](#))

Hatfield KJ, Lassalle P, Leiva RA, Lindås R, Wendelboe O and Bruserud O (2011) *Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia.* Hematology 16(6):351-6 ([Pubmed](#))

Mikkelsen ME, Shah C, Scherpereel A, Lanken PN, Lassalle P, Bellamy SL, A. Localio R, Albelda SM, Meyer NJ and Christie JD (2011) *Lower serum endocan levels are associated with the development of acute lung injury after major trauma.* J. Crit. Care. In Press ([Pubmed](#))

Publications in 2010

Leroy X, Aubert S, Zini L, Franquet H, Kervoaze G, Villers A, Delehedde M, Copin MC and Lassalle P (2010) *Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma.* Histopathol. 56(2):180-187 ([Pubmed](#))

Parmentier E, de Freitas Caires N, Grigoriu B, Pastré J, Palud A, Delehedde M, Mathieu D, Scherpereel A and Lassalle P (2010) *Endocan (endothelial cell-specific molecule-1) as a pertinent biomarker of endothelial dysfunction in sepsis.* Crit. Care. 14:P55 ([Crit Care](#))

Pastré J, De Freitas Caires N, Delehedde M, Scherpereel A, Parmentier E, Mathieu D and Lassalle P (2010) *Differential kinetics of endothelial cell activation biomarkers E-selectin and endocan during nonlethal endotoxemia in 129Sv mice: a role for PMN-derived serine proteases in the transient decrease of circulating endocan levels.* Crit. Care 14:P42 ([Crit Care](#))

Reikvam H, Hatfield KJ, Lassalle P, Kittang AO, Ersvaer E and Bruserud Ø (2010) *Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.* Expert. Opin. Investig. Drugs. (2):169-183 ([Pubmed](#))

Sarrazin S, Lyon M, Deakin JA, Guerrini M, Lassalle P, Delehedde M and Lortat-Jacob H (2010) *Characterization and binding activity of the chondroitin/dermatan sulfate chain from Endocan, a soluble endothelial proteoglycan.* Glycobiol. 20(11):1380-1388 ([Pubmed](#))

Sarrazin S, Maurage CA, Delmas D, Lassalle P and Delehedde M (2010) *Endocan as a biomarker of endothelial dysfunction in cancers.* J. Cancer. Sci. Ther. 2:47-52 ([PDF](#))

Publications in 2009

De Freitas Caires N, Barrier M, Sarrazin S, Depontieu , Ghamlouch H, Morelle W, Drobecq H, Delehedde M, Lortat-Jacob H, Duez C, Scherpereel A and Lassalle P (2009) *In vitro pathways of vascular endocan catabolism and their relevance in sepsis.* Am. J. Respir. Crit. Care Med. 179:A1156 ([Atsjournals](#))

De Freitas Caires N, Barrier M, Sarrazin S, Depontieu F and Ghamlouch H (2009) *Identification of cathepsin G in the generation of elastase-resistant fragment of vascular endocan: involvement in the regulation of LFA-1-dependent cascade.* Crit. Care 13: P16 ([Pubmed](#))

Hatfield K, Øyan AM, Ersvaer E, Kalland KH, Lassalle P, Gjertsen BT and Bruserud Ø (2009) *Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators.* Br. J. Haematol. 144: 53-68 ([Pubmed](#))

Maurage CA, Adam E, Mineo JF, Sarrazin S, Debunne M, Siminski RM, Baroncini M, Lassalle P, Blond S and Delehedde M (2009) *Endocan expression and localization in human glioblastomas.* J. Neuropathol. Exp. Neurol. 68(6):633-641 ([Pubmed](#))

Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT and Bruserud O (2009) *A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.* Leuk. Res. 33(6):779-787 ([Pubmed](#))

Shah CV, Scherpereel A, Lanken PN, Lassalle P, Gallop R, Bellamy S, Localio AR, Fuchs BD, Albelda SM, De Freitas Caires N, Meyer NJ and Christie JD (2009) *Lower serum endocan levels are associated with the development of acute lung injury after major trauma.* Am. J. Respir. Crit. Care Med. 179:A4649 ([Atsjournals](#))

Publications in 2008

Adam E, Sarrazin S, Landolfi C, Motte V, Lortat-Jacob H, Lassalle P and Delehedde M (2008) *Efficient long-term and high-yielded production of a recombinant proteoglycan in eukaryotic HEK293 cells using a membrane-based bioreactor.* Biochem. Biophys. Res. Commun. 369(2):297-302 ([Pubmed](#))

De Freitas Caires N, Domisse L, Forez C, Hauw P and Lassalle P (2008) *Catabolisme d'endocan au cours du choc endotoxique.* Rev. Mal. Resp. 25(9):1188 ([Elsevier](#))

Depontieu F, Grigoriu BD, Scherpereel A, Adam E, Delehedde M, Gosset P and Lassalle P (2008) *Loss of Endocan tumorigenic properties after alternative splicing of exon 2.* BMC Cancer. 8:14-21 ([Pubmed](#))

Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT and Bruserud O (2008) *In vivo biological effects of ATRA in the treatment of AML.* Expert. Opin. Investig. Drugs. (11):1623-33 ([Pubmed](#))

Publications in 2007

Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameer A, Westholm JO, Komorowski J, Lassalle P, Cross MJ and Gerwins P (2007) *Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer.* Exp. Cell. Res. 313(7):1285-1294 ([Pubmed](#))

Publications in 2006

Delehedde M, Sarrazin S, Adam E, Motte V and Vanpouille C (2006) *Proteoglycans and glycosaminoglycans: Complex molecules with modulating activity.* In: *New Developments in Therapeutic Glycomics*, Delehedde & Lortat-Jacob, eds. Kerala: Research Signpost, p 1-13 ([Pubmed](#))

Filep JG (2006) *Endocan or endothelial cell-specific molecule-1: a novel prognostic marker of sepsis?* Crit. Care Med. 34(2):574-57 ([Pubmed](#))

Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, Lafitte JJ, Copin MC, Tonnel AB and Lassalle P (2006) *Endocan expression and relationship with survival in human non-small cell lung cancer.* Clin. Cancer Res. 12(15):4575-4582 ([Pubmed](#))

Janke J, Engeli S, Gorzelniak K, Feldpausch M, Heintze U, Bohnke J, Wellner M, Herse F, Lassalle P, Luft FC and Sharma AM (2006) *Adipose tissue and circulating endothelial cell specific molecule-1 in human obesity.* Horm. Metab. Res. 38(1):28-33 ([Pubmed](#))

Lassalle P, Adam E, Sarrazin S, Deponthieu F, Motte V, Lequien S, Grigoriu B, De Freitas-Caires N, Vanpouille C and Delehedde M (2006) *Proteoglycans and glycosaminoglycans : key players in inflammation.* In: *New Developments in Therapeutic Glycomics*, Delehedde & Lortat-Jacob, eds. Kerala: Research Signpost, p 15-31 ([Pubmed](#))

Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P and Delehedde M (2006) *Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy.* Biochim. Biophys. Acta. Reviews. 1765(1):25-37 ([Pubmed](#))

Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, Jourdain M, Pugin J, Tonnel AB and Lassalle P (2006) *Endocan, a new endothelial marker in human sepsis.* Crit. Care Med. 34(2):532-537 ([Pubmed](#))

Publications in 2005

Delehedde M, Lortat-Jacob H, Gallagher JT, Bonnaffe D, Adam E, Querolle O, Lequien S, Degove S, Lassalle P and Bechard D (2005) *Proteoglycan involvement in inflammatory diseases. New developments in GAG-based therapies.* Med. Chem. Reviews. 2:345-357 ([Pubmed](#))

Publications in 2004

Grigoriu BD and Tonnel AB (2004) *Rôle d'endocan dans la croissance des tumeurs broncho-pulmonaires expérimentales chez la souris et effets des anticorps monoclonaux anti-endocan sur le développement tumoral.* Rev. Mal. Resp. 21(2): 423 ([Elsevier](#))

Sarrazin S, Bechard D, Lassalle P, Lyon M, Scherpereel A, Lortat-Jacob H, Ouatas T and Delehedde M (2004) *Purification and characterization of endocan (endothelial cell-specific molecule-1), a circulating proteoglycan involved in tumour progression and inflammatory diseases*. Int. J. Exp. Pathol. 85(4):A73 ([Ingenta](#))

Tissier S, Lancel S, Marechal X, Mordon S, Depontieu F, Scherpereel A, Chopin C and Neviere R (2004) *Calpain inhibitors improve myocardial dysfunction and inflammation induced by endotoxin in rats*. Shock. 21(4):352-357 ([Pubmed](#))

Publications in 2003

Scherpereel A, Gentina T, Grigoriu B, Senechal S, Janin A, Tsicopoulos A, Plenat F, Bechard D, Tonnel AB and Lassalle P (2003) *Overexpression of endocan induces tumor formation*. Cancer. Res. 63(18):6084-6089 ([Pubmed](#))

Publications in 2002

Delehedde M, Allain F, Payne SJ, Borgo R, Vanpouille C, Fernig DG and Deudon E (2002) *Proteoglycans in inflammation*. Curr. Med. Chem. 1:89-102 ([Pubmed](#))

Trowbridge JM and Gallo RL (2002) *Dermatan sulfate: new functions from an old glycosaminoglycan*. Glycobiol. 12(9):117-125 ([Pubmed](#))

Tsai JC, Zhang J, Minami T, Voland C, Zhao S, Yi X, Lassalle P, Oettgen P and Aird WC (2002) *Cloning and characterization of the human lung endothelial-cell-specific molecule-1 promoter*. J. Vasc. Res. 39(2):148-159 ([Pubmed](#))

Publications in 2001

Bechard D, Gentina T, Delehedde M, Scherpereel A, Lyon M, Aumercier M, Vazeux R, Richet C, Degand P, Jude B, Janin A, Fernig DG, Tonnel AB and Lassalle P (2001) *Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity*. J. Biol. Chem. 276(51):48341-48349 ([Pubmed](#))

Bechard D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, Aumercier M, Pestel J, Dessaint JP, Tonnel AB and Lassalle P (2001) *Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1*. J. Immunol. 167(6):3099-3106 ([Pubmed](#))

Publications in 2000

Bechard D, Meignin V, Scherpereel A, Oudin S, Kervoaze G, Bertheau P, Janin A, Tonnel A and Lassalle P (2000) *Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies*. J. Vasc. Res. 37(5):417-425 ([Pubmed](#))

Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, Devos R and Tonnel AB (1996) *ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines*. J. Biol. Chem. 271:20458-20464 ([Pubmed](#))